Most Recent Articles by Kathy Boltz, PhD
A previous history of cancer cancer did not impact clinical outcomes in advanced lung cancer patients and these patients therefore should be considered for inclusion in clinical trials, according to a study .
The American Society for Radiation Oncology (ASTRO) has signaled their approval of the decision by the Centers for Medicare and Medicaid Services to provide coverage for annual lung cancer screening for those at very high risk for lung cancer.
Research indicates a high value of scans that could lead to future change of reimbursement policies for follow-up PET/CT studies in lung cancer.
The pioneering prostate cancer drug abiraterone can significantly extend the lives of men with advanced prostate cancer if administered prior to administering chemotherapy, according to phase III clinical trial data.
New research suggests that active surveillance may be an initial approach for men with favorable intermediate-risk prostate cancer.
More Articles by Kathy Boltz, PhD
- New mechanism of acquired resistance to breast cancer drugs discovered
- Finding a qualified acupuncture practitioner
- Two major studies strengthen case for prostate cancer drug before chemotherapy
- Crucial role of breast cancer tumor suppressor revealed
- Study may support active surveillance for favorable intermediate-risk prostate cancer
- Cancer survivors need not be excluded from advanced stage lung cancer trials
- Fried food consumption associated with increased risk for heart failure
- Focus groups identify support needs of patients who smoke
- Twitter smoking cessation program helps smokers quit
- ASTRO applauds CMS decision to cover annual screening for high-risk lung cancer patients
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|